Ended Therapeutic exploratory (Phase II) Mild Cognitive impairment due to Alzheimer Disease

A single-center study to assess the effect of lamivudine (3TC) on cognitive impairment (alterations in thinking, learning, memory...) by the analysis of the plasma of patients with Mild Cognitive Impairment (MCI)

EU CTIS ID: 2024-514330-20-00

What this study is testing

To assess the ability of lamivudine to lower the levels of neurocognitive impairment biomarkers and type-I IFN-stimulated genes in the plasma of patients with MCI and positive AD biomarkers in a 24 weeks-treatment period. To assess the incidence, nature, and severity of Treatment Emergent Adverse Events (TEAE).

Therapeutic exploratory (Phase II)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

1. Male or female participants 55 to 90 years of age (both inclusive) at the time of signing the informed consent.
10. A male participant must agree to use a highly effective contraception method during the treatment period and for at least 3 months after the last dose of study treatment and refrain from donating sperm during this period.
11. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use a highly effective contraception method during the treatment period and for at least 3 months after the last dose of study treatment.
12. Written informed consent provided by participant (or legal representative) and caregiver prior to any study-specific procedures.
2. Diagnosis of prodromal AD: MCI due to AD according to National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria as determined by a neurologist, geriatrician, psychiatrist, or clinician approved by the Sponsor or designee.
3. Clinical Dementia Rating (CDR)-Global Score of 0.5

You likely can't join if

1. Possible, probable, or definite vascular dementia according to the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l’Enseignement en Neurosciences (NINDS-AIREN) criteria.
18. Resides in a moderate to high dependency continuous care facility (residence in low grade assisted living facility where there is sufficient autonomy to permit valid evaluation of activities of daily living is allowed).
19. Any other reason that in the opinion of the investigator would make the participant ineligible to participate or to complete this study.
2. Evidence of significant abnormality that would suggest another potential etiology for dementia (e.g., evidence of cerebral contusion, encephalomalacia, aneurysm, vascular malformation, > 10 microhemorrhages, macrohemorrhage, single infart > 1 cm3).
20. Refrain from donating blood or blood products from the screening visit until 3 months after the EOS/ET visit.
3. Other central nervous system diseases that may cause cognitive impairment (e.g., cerebrovascular disease including cerebrovascular dementia, Parkinsonism, Huntington’s disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, Creutzfeldt-Jakob disease).

See the full eligibility criteria

Who can join

1. Male or female participants 55 to 90 years of age (both inclusive) at the time of signing the informed consent.
10. A male participant must agree to use a highly effective contraception method during the treatment period and for at least 3 months after the last dose of study treatment and refrain from donating sperm during this period.
11. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to use a highly effective contraception method during the treatment period and for at least 3 months after the last dose of study treatment.
12. Written informed consent provided by participant (or legal representative) and caregiver prior to any study-specific procedures.
2. Diagnosis of prodromal AD: MCI due to AD according to National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria as determined by a neurologist, geriatrician, psychiatrist, or clinician approved by the Sponsor or designee.
3. Clinical Dementia Rating (CDR)-Global Score of 0.5
4. Imaging studies (MRI or CT) within 2 years prior to screening that exclude secondary causes of dementia.
5. Documented confirmation of AD diagnosis by positive CSF AD signature or positive amyloid-PET. CSF AD positivity established with low levels of CSF Aβ1-42 or CSF Aβ1-42/Aβ1-40 and high levels of p-Tau. A CSF examination performed within 12 months prior to screening is allowed. A positive amyloid-PET is defined as abnormal deposits of amyloid in the PET imaging.
6. If receiving an approved medication for AD (i.e., donepezil, galantamine, rivastigmine, memantine, or memantine/donepezil combination product), must be on the medication with a stable dose for at least 4 weeks before the screening visit (dosing should remain stable throughout the study).
7. If receiving an OTC supplement for cognition (e.g., gingko biloba, omega-3 polyunsaturated fatty acid, vitamin E, curcumin), must not be exceeding the recommended dose and be at stable dose for at least 4 weeks prior to screening visit.
8. Able to visit the study center and undergo cognitive, functional, and other tests specified in the protocol.
9. In the event that the participant requires a caregiver, the caregiver: a. Agrees to accompany the participant to all study visits and able to supervise the participant’s compliance with the study procedures and provide detailed information about the participant. b. Either lives with the participant or sees the participant on average for ≥ 1 hour/day ≥ 3 days/week, or in the Investigator’s opinion, the extent of contact is sufficient to provide meaningful assessment of changes in participant behavior and function over time and provide information on safety and tolerability. c. Can read, understand, and speak the designated language at the study center. d. Caregiver must be cognitively able to fulfill the requirements of the study.

What rules you out

1. Possible, probable, or definite vascular dementia according to the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l’Enseignement en Neurosciences (NINDS-AIREN) criteria.
18. Resides in a moderate to high dependency continuous care facility (residence in low grade assisted living facility where there is sufficient autonomy to permit valid evaluation of activities of daily living is allowed).
19. Any other reason that in the opinion of the investigator would make the participant ineligible to participate or to complete this study.
2. Evidence of significant abnormality that would suggest another potential etiology for dementia (e.g., evidence of cerebral contusion, encephalomalacia, aneurysm, vascular malformation, > 10 microhemorrhages, macrohemorrhage, single infart > 1 cm3).
20. Refrain from donating blood or blood products from the screening visit until 3 months after the EOS/ET visit.
3. Other central nervous system diseases that may cause cognitive impairment (e.g., cerebrovascular disease including cerebrovascular dementia, Parkinsonism, Huntington’s disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, Creutzfeldt-Jakob disease).
4. Concurrent or history of clinically significant psychiatric conditions (e.g., schizophrenia or bipolar affective disorder) that in the Investigator’s opinion prevents the participant from participating or is likely to confound interpretation of drug effect or affect cognitive assessments.
5. Vitamin B12, folic acid, syphilis serology, and thyroid stimulating hormone (TSH) results that are thought to contribute to the severity of dementia or cause dementia. Participants may be enrolled if in the Investigator’s medical judgment, the abnormal laboratory values are not the cause of the cognitive symptoms.
6. History of known or suspected seizures including febrile seizures (excluding self-limited childhood febrile seizures), a history of significant head trauma with loss of consciousness or recent unconsciousness that is not explained.
7. Acute or unstable cardiovascular disease, active peptic ulcer, uncontrolled hypertension, uncontrolled diabetes or any medical condition that may interfere with the completion of the clinical study.
8. Known allergies, hypersensitivity, or intolerance to lamivudine or similar products or excipients.
10. Concurrent malignancies or invasive cancers diagnosed within the past 3 years except for non-metastatic basal cell carcinoma or squamous cell carcinoma of skin, in situ carcinoma of the uterine cervix or non-metastatic prostate càncer.
9. History of alcohol, substance abuse or dependence as per DSM-V criteria (except nicotine dependence) within the last 3 years.
21. Positive blood screen for Human Immunodeficiency Virus (HIV-1 and 2).
11. Sexually active WOCBP or man capable of fathering a child who do not consent to using medicinally acceptable contraception (such as surgical sterilization, intrauterine contraceptive device, condom, or diaphragm, an injectable or inserted contraceptive) during the study and for 3 months after the last dose of study treatment.
12. Use of anxiolytics, narcotics, or sleep aids in a manner that would interfere with cognitive testing, in the opinion of the investigator. Atypical antipsychotics may be used at the discretion of the Investigator. Tricyclic antidepressants and monoamine oxidase (MAO) inhibitors may be used at the discretion of the investigator.
13. Previous treatment with lamivudine.
14. Received an investigational product for AD within the last 3 months.
15. Participated in another clinical study within 4 weeks prior to this study.
16. Subject has any of the following laboratory findings at screening: a. Severe liver dysfunction (Alanine aminotransferase > 2x upper limit of normal (ULN), aspartate aminotransferase > 2x ULN, or history of clinically significant liver disease in the investigator’s judgment. b. Hemoglobin ≤ 10 g/dl. c. International Normalized Ratio (INR) > 1.5 or total bilirubin > 1.5 x ULN (unless subject has evidence of Gilbert’s disease). d. Renal impairment Creatinine clearance (CrCl) < 45 ml/min. e. Poorly controlled diabetes as defined by hemoglobin A1C (HbA1C) > 8.
17. Body weight ≤ 35 kg.

The study team makes the final eligibility decision.

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.

Explore other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH)Heart failure Coronary artery disease

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.